Zielińska-Pisklak M - Search Results

1

Comparison of the analytical methods (solid state NMR, FT-IR, PXRD) in the analysis of the solid drug forms with low concentration of an active ingredient - 17-β-estradiol case.

Szeleszczuk Ł, Jurczak E, Zielińska-Pisklak M, Harwacki J, Pisklak DM. Szeleszczuk Ł, et al. J Pharm Biomed Anal. 2018 Feb 5;149:160-165. doi: 10.1016/j.jpba.2017.11.015. Epub 2017 Nov 6. J Pharm Biomed Anal. 2018. PMID: 29121569

2

1H and 13C NMR characteristics of β-blockers.

Zielińska-Pisklak MA, Pisklak DM, Wawer I. Zielińska-Pisklak MA, et al. Magn Reson Chem. 2011 May;49(5):284-90. doi: 10.1002/mrc.2742. Epub 2011 Mar 29. Magn Reson Chem. 2011. PMID: 21491484

3

Application of 13C CPMAS NMR for qualitative and quantitative characterization of carvedilol and its commercial formulations.

Zielińska-Pisklak M, Pisklak DM, Wawer I. Zielińska-Pisklak M, et al. J Pharm Sci. 2012 May;101(5):1763-72. doi: 10.1002/jps.23062. Epub 2012 Feb 13. J Pharm Sci. 2012. PMID: 22331650

4

¹³C cross-polarization magic-angle spinning nuclear magnetic resonance analysis of the solid drug forms with low concentration of an active ingredient-propranolol case.

Pisklak DM, Zielińska-Pisklak M, Szeleszczuk L, Wawer I. Pisklak DM, et al. J Pharm Biomed Anal. 2014 May;93:68-72. doi: 10.1016/j.jpba.2013.06.031. Epub 2013 Jul 5. J Pharm Biomed Anal. 2014. PMID: 23911072

5

Activity-guided isolation, identification and quantification of biologically active isomeric compounds from folk medicinal plant Desmodium adscendens using high performance liquid chromatography with diode array detector, mass spectrometry and multidimentional nuclear magnetic resonance spectroscopy.

Zielińska-Pisklak MA, Kaliszewska D, Stolarczyk M, Kiss AK. Zielińska-Pisklak MA, et al. J Pharm Biomed Anal. 2015 Jan;102:54-63. doi: 10.1016/j.jpba.2014.08.033. Epub 2014 Sep 6. J Pharm Biomed Anal. 2015. PMID: 25240729

6

¹³C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations Part II: CP kinetics and relaxation analysis.

Pisklak DM, Zielińska-Pisklak M, Szeleszczuk Ł, Wawer I. Pisklak DM, et al. J Pharm Biomed Anal. 2016 Apr 15;122:29-34. doi: 10.1016/j.jpba.2016.01.030. Epub 2016 Jan 16. J Pharm Biomed Anal. 2016. PMID: 26836362

7

¹³C solid-state NMR analysis of the most common pharmaceutical excipients used in solid drug formulations, Part I: Chemical shifts assignment.

Pisklak DM, Zielińska-Pisklak MA, Szeleszczuk Ł, Wawer I. Pisklak DM, et al. J Pharm Biomed Anal. 2016 Apr 15;122:81-9. doi: 10.1016/j.jpba.2016.01.032. Epub 2016 Jan 22. J Pharm Biomed Anal. 2016. PMID: 26845204

8

Application of ¹³C NMR cross-polarization inversion recovery experiments for the analysis of solid dosage forms.

Pisklak DM, Zielińska-Pisklak M, Szeleszczuk Ł. Pisklak DM, et al. Int J Pharm. 2016 Nov 20;513(1-2):538-542. doi: 10.1016/j.ijpharm.2016.09.066. Epub 2016 Sep 22. Int J Pharm. 2016. PMID: 27667758

9

Spectroscopic and structural studies of the diosmin monohydrate and anhydrous diosmin.

Szeleszczuk Ł, Pisklak DM, Zielińska-Pisklak M, Wawer I. Szeleszczuk Ł, et al. Int J Pharm. 2017 Aug 30;529(1-2):193-199. doi: 10.1016/j.ijpharm.2017.06.078. Epub 2017 Jun 27. Int J Pharm. 2017. PMID: 28663085

10

Does the choice of the crystal structure influence the results of the periodic DFT calculations? A case of glycine alpha polymorph GIPAW NMR parameters computations.

Szeleszczuk Ł, Pisklak DM, Zielińska-Pisklak M. Szeleszczuk Ł, et al. J Comput Chem. 2018 May 30;39(14):853-861. doi: 10.1002/jcc.25161. Epub 2018 Jan 5. J Comput Chem. 2018. PMID: 29315751

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

23 results

Search Page